• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Infections Caused By Picornaviridae - Pipeline Review, H2 2012 Product Image

Infections Caused By Picornaviridae - Pipeline Review, H2 2012

  • Published: August 2012
  • 41 pages
  • Global Markets Direct

Infections Caused By Picornaviridae – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Infections Caused By Picornaviridae - Pipeline Review, H2 2012', provides an overview of the Infections Caused By Picornaviridae therapeutic pipeline. This report provides information on the therapeutic development for Infections Caused By Picornaviridae, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Infections Caused By Picornaviridae. 'Infections Caused By Picornaviridae - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Infections Caused READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Infections Caused By Picornaviridae Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Infections Caused By Picornaviridae 7
Infections Caused By Picornaviridae Therapeutics under Development by Companies 9
Infections Caused By Picornaviridae Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Infections Caused By Picornaviridae Therapeutics – Products under Development by Companies 14
Infections Caused By Picornaviridae Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Infections Caused By Picornaviridae Therapeutics Development 16
Sinovac Biotech Ltd. 16
Inviragen, Inc. 17
Infections Caused By Picornaviridae – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
EV71 Vaccine - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
SLP1001 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
SLP0904 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
HFMDVax - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Vero Cell - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Infections Caused By Picornaviridae Therapeutics – Drug Profile Updates 29
Infections Caused By Picornaviridae – Product Development Milestones 32
Featured News & Press Releases 32
Jul 27, 2012: Fluoxetine Effective As Anti-Viral, UCLA Researchers Discover 32
Jun 25, 2012: Sinovac Reports Progress In EV71 Vaccine Phase III Clinical Trial And Commercialization Preparation Status 33
Jun 11, 2012: Sinovac Reports Progress In EV71 Vaccine Phase III Clinical Trial 34
Mar 29, 2012: Sinovac Announces Publication Of Phase I Clinical Data Of EV71 Vaccine For Prevention Of Hand, Foot And Mouth Disease In Journal Vaccine 34
Jan 10, 2012: Sinovac Commences Phase III Clinical Trial For EV71 Vaccine Against Hand, Foot And Mouth Disease 35
Nov 09, 2011: Sinovac Reports Positive Preliminary Phase II Clinical Trial Results For EV71 Vaccine Against Hand, Foot And Mouth Disease 36
Jun 28, 2011: Sinovac Commences Phase II Clinical Trial For EV71 Vaccine 36
May 25, 2011: Sinovac Reports Positive Phase I Clinical Trial Results For EV71 Vaccine Against HFMD 37
Mar 10, 2011: Sinovac Reports Positive Preliminary Phase I Clinical Trial Results For EV71 Vaccine In Adult Group 38
Dec 28, 2010: Sinovac Receives SFDA Approval To Commence Clinical Trials For Inactivated Enterovirus Type 71 Vaccine 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products Under Development for Infections Caused By Picornaviridae, H2 2012 7
Products under Development for Infections Caused By Picornaviridae – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Sinovac Biotech Ltd., H2 2012 16
Inviragen, Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Infections Caused By Picornaviridae Therapeutics – Drug Profile Updates 29

List of Figures
Number of Products under Development for Infections Caused By Picornaviridae, H2 2012 7
Products under Development for Infections Caused By Picornaviridae – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos